TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TransMedics Group, Inc. (Nasdaq: TMDX), a leader in organ transplant technology, will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. The event is scheduled for September 12, 2022, at 11:40 a.m. ET at the Sheraton New York. The management team will engage in a fireside chat, which will be accessible via a live and archived webcast on the company's investors' webpage.
TransMedics focuses on enhancing organ quality and viability assessments to improve transplant outcomes for patients with end-stage organ failure.
Details
News Market Reaction – TMDX
The recorded move for TMDX in the trading session of this news was -3.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANDOVER, Mass., Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York. The fireside chat will take place on Monday, September 12, 2022, at 11:40 a.m. Eastern Time.
Event: Morgan Stanley 20th Annual Global Healthcare Conference
Date: Monday, September 12, 2022
Time: 11:40 a.m. ET
A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-conference-301613980.html
SOURCE TransMedics Group, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.